In Part 5 of our Life Sciences Industry Report, we turn our attention to the oncological field of research and development, from cancer therapies to cancer care, from clinical trials to the patient’s ...

Take a look at three predictions for the year ahead for pharma executives considering AI implementation and adoption. For AI to live up to its potential, pharma executives need to not simply invest in ...

Spinraza remains a big product for Biogen but has seen its sales go into reverse as competition in SMA treatment has emerged ...

BV100 is a new formulation of rifabutin suitable for intravenous administration that BioVersys claims offers a new mechanism ...

President Trump's pick to lead the Department of Health and Human Services (HHS), Robert F Kennedy Jr, will be scrutinised at ...

The innovation showcased at CES highlights how practical solutions can meet niche, but impactful, health challenges. These ...

The ranges were 4.5 to nine years for men and 6.5 to 11 years for women, according to the researchers, who have published ...

The new data comes from the phase 3 ALLEVIATE-1 trial, which compared cebranopadol to placebo for the management of ...

AstraZeneca has launched a separate business unit that will take what the drugmaker has learned from running digitally-powered clinical trials and offer that experience to other sponsors.

In a dramatic change in fortunes, Novartis has won a major victory in its bid to defend oral multiple sclerosis therapy Gilenya from early generic competition in the US. Things have been looking ...

It’s always a good sign when a couple of big deals are announced right before the conference, and this year we saw a doozie ...

At the conference last week in San Francisco, pharmaphorum editor-in-chief Jonah Comstock spoke with Vir Biotechnology CEO Marianne De Backer, who explained a bit more about what a dual-masked T-cell ...